Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2008
08/14/2008US20080194615 Substituted Tetrahydroquinolines
08/14/2008US20080194614 Using mixture of hydroxy-3-methylglutaryl coenzyme a inhibitor and rapamycin; anticholesterol agents; dyslipidemia; atherosclerosis; antiarthritic agents; inflammatory bowel disorders; restenosis; transplant rejection
08/14/2008US20080194613 P53 Wild-Type as Biomarker for the Treatment with Mtor Inhibitors in Combination With a Cytotoxic Agent
08/14/2008US20080194612 Water soluble ; polymer joining active materials; antitumor agents
08/14/2008US20080194611 Modulation of Cell Barrier Dysfunction
08/14/2008US20080194610 e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indol-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder
08/14/2008US20080194609 Chemical Compound and Its Use
08/14/2008US20080194608 Atherosclerosis therapy; antidiabetic agents; dyslipidemia
08/14/2008US20080194607 Modulation of pathogenicity
08/14/2008US20080194606 Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer
08/14/2008US20080194605 Antitumor agents; kinase inhibitors; angiogenesis inhibitors; arteriosclerosis ; antiinflammatory agents
08/14/2008US20080194604 Dissolving with anionic surfactant while controlling temperature; dehydration; stirring; filtration; hydroxy-3-methylglutaryl/3-/coenzyme a inhibitor; suppression of cholesterol biosynthesis
08/14/2008US20080194603 Prevent transplant rejection; autoimmune diseases
08/14/2008US20080194602 Mixing of active material with carrier; viricides
08/14/2008US20080194601 Intermittent administering over a long time; by injection; using (4-((4-((2-cyanoethenyl)-2,3-dimethylphenyl )amino)2-pyrimidyl)amino)benzonitrile
08/14/2008US20080194600 Antiallergens; vision defects; skin disorders; antiinflammatory agents; infection therapy; sleep disorders; antiinflammatory agents; chronic obstructive pulmonary disorders; antiarthritic agents; antiulcer agents; inflammatory bowel disorders
08/14/2008US20080194598 Pyrimidine Carboxylic Acid Derivatives and Use Thereof
08/14/2008US20080194597 Platelet adp receptor inhibitors
08/14/2008US20080194596 Therapeutic Combination Including a Selective Erbb2 Inhibitor
08/14/2008US20080194595 Quinazolinone Derivatives Useful as Vanilloid Antagonists
08/14/2008US20080194594 Hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, or diabetes; can be used in combination with an anti-hemorrhagic viral infection agent, an immunosuppressant; kits
08/14/2008US20080194593 Asthma therapy; antidiarrhea agents; antiinflammatory agents; gastrointestinal disorders; anticancer agents; cardiovascular disorders
08/14/2008US20080194592 Organic Compounds
08/14/2008US20080194591 Anhydrous Crystalline Forms Of N-[1-(2-Ethoxyethyl)-5-(N-Ethyl-N-Methylamino)-7-(4-Methylpyridin-2-Yl-Amino)-1H-Pyrazolo[4,3-D]Pyrimidine-3-Carbonyl]Methanesulfonamide
08/14/2008US20080194590 Thrombosis therapy
08/14/2008US20080194589 Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists
08/14/2008US20080194588 Modulation of pathogcnicity
08/14/2008US20080194587 phosphodiesterase inhibitor; drug for respiratory system disorders
08/14/2008US20080194586 Controlling non-insulin dependent diabetes; hypoglycemic agents; antilipemic agents; hypercholesterolemia; obesity
08/14/2008US20080194584 Nitrogen Heteroaromatic Compounds Which Bind To The Active Site Of Protein Kinase Enzymes
08/14/2008US20080194583 Tubulin Inhibitors
08/14/2008US20080194582 3,5-Diphenyl-4,5-dihydro-1H-dipyrazole derivatives such as {2-[1-acetyl-3-(2,5-difluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-5-yl]ethyl}(dimethyl)silanol that are useful for treating cancer
08/14/2008US20080194581 Pyrrole derivatives, intermediates therefor, preparation and therapeutic use thereof
08/14/2008US20080194580 Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas
08/14/2008US20080194579 Antiinflammatory agents; chronic obstructive pulmonary disease; antihistamines; transplant rejection; antitumor agents
08/14/2008US20080194578 Quinazoline based egfr inhibitors containing a zinc binding moiety
08/14/2008US20080194577 Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents
08/14/2008US20080194576 Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists
08/14/2008US20080194575 Treatment for non-alcoholic-steatohepatitis
08/14/2008US20080194574 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
08/14/2008US20080194573 3-(Heteroaryl-Oxy)-2-Alkyl-1-Aza-Bicycloalkyl Derivatives As Alpha. 7-Nachrligands For TheTreatment Of Cns Diseases
08/14/2008US20080194572 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
08/14/2008US20080194571 Acetylenic Piperazines as Metabotropic Glutamate Receptor Antagonists
08/14/2008US20080194570 SOLID PHARMACEUTICAL FORMULATIONS OF A HOMOGENEOUS DISPERSION OF ACTIVE PRINCIPLES HAVING pH-DEPENDENT SOLUBILITY
08/14/2008US20080194569 Phthalazinones
08/14/2008US20080194568 Pyridomorphinans, Pyridazinomorphinans and Use Thereof
08/14/2008US20080194567 promoting diuresis in a patient comprises administering levosimendan or its active metabolite or any of their pharmaceutically acceptable salts in conjunction with a diuretic to a patient. The combination therapy provides diuretic effect also in patients who are refractory to standard diuretic therapy
08/14/2008US20080194565 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases
08/14/2008US20080194564 the use thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions comprising them, and processes for the preparation of these
08/14/2008US20080194563 small molecule protein tyrosine phosphatase inhibitorsuse of said compounds for the treatment of phosphatase-mediated diseases, especially cancer
08/14/2008US20080194562 Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
08/14/2008US20080194561 Compounds
08/14/2008US20080194560 a rapidly disintegrating solid dosage form comprising an active pharmaceutical ingredient, a disintegrant and a disintegration promoter, which formulation is obtainable by a wet granulation process
08/14/2008US20080194559 Remedy for Angiospasm Accompanying Subarachnoid Hemorrhage Containing Thrombin Receptor Antagonist as the Active Ingredient
08/14/2008US20080194558 Quinazoline analogs as receptor Tyrosine Kinase inhibitors
08/14/2008US20080194557 methods of treating, managing and preventing pain, inflammation, cancer, and ocular diseases and disorders, and to compounds and pharmaceutical compositions useful in such methods
08/14/2008US20080194556 Quinazolines and Their Use as Aurora Kinase Inhibitors
08/14/2008US20080194555 Tyrosine kinase inhibitors; antiproliferation agents; metabolism diseases; antiallergens; central nervous system disorders; vision and skin disorders; antiarthritic agents
08/14/2008US20080194554 compounds that are HIV protease inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.
08/14/2008US20080194553 compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition,in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome
08/14/2008US20080194552 Aminopyrimidine Derivatives With Tie2 Inhibiting Activity
08/14/2008US20080194551 Acetylene Derivatives
08/14/2008US20080194550 optical isomer thereof, or a corresponding acid addition salt thereof with a pharmacologically acceptable acid, and the use thereof as pharmaceutical compositions, particularly for the treatment of inflammatory and obstructive respiratory complaints.
08/14/2008US20080194549 Organic Compounds
08/14/2008US20080194548 combination of a CCR2 antagonist and a statin is useful in the treatment and or prevention of inflammatory and other disorders, and methods of treating inflammatory and other disorders using a combination of a CCR2 antagonist and a statin.
08/14/2008US20080194547 6-{[(3-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-azabicyclo[3.1.0]hex-6-yl)amino]methyl}-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli
08/14/2008US20080194546 wherein: one or two of X5, X6 and X8 is N, and the others are CH; R7 is selected from halo, ORO1, SRS1, NRN1RN2, NRN7aC( .dbd. O)RC1, NRN7bSO2RS2a, an optionally substituted C5-20 heteroaryl group, or an optionally substituted C5-20 aryl group, where RO1 and RS1 are selected from H,
08/14/2008US20080194545 Antimicrobial compositions and methods of use
08/14/2008US20080194544 Also containing propylene glycol, hydroxypropyl methyl cellulose, a buffer, preservative and chelate compound; nose sprays; no bitter taste
08/14/2008US20080194543 Immunosuppressive Ningalin Compounds
08/14/2008US20080194542 Wherein the two drugs are not physically separated from each other, there are no alkali and alkaline earth metal carbonates and phosphates, and no excipients which increase the pH of microenvironment above 5; improved stability
08/14/2008US20080194541 Anti-Inflammatory Agents
08/14/2008US20080194540 Desipramine, imipramine, trimipramine, amitriptyline, nortriptyline, doxepin, amoxapine, or maprotyline and chloroquine, promazine, quinine, biquinoline, phenothiazine or chlorpromazine; transfection or gene therapy
08/14/2008US20080194539 Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists
08/14/2008US20080194538 Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor
08/14/2008US20080194537 Tetrapeptide capable of inhibiting binding of the Smac protein to Inhibitors of apoptosis, thus promoting apoptosis or sensitizing cells; antiproliferative and anticarcinogenic agents
08/14/2008US20080194536 Cyanoarylamines
08/14/2008US20080194535 2-ethyl-hexanoic acid ((1S,4R,5S,8S,14R)-5-benzyl-4-hydroxy-18-methoxy-7-oxo-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10, 15(20),16,18-tetraen-8-yl)-methyl-amide; Alzheimer's Disease, Down's Syndrome; inhibitors of beta-secretase processing of amyloid precursor proteins
08/14/2008US20080194534 Retinoic esters with cholesterol; antiproliferative agents; disorders caused by abnormal cellular differentiation; psoriasis, cancers of skin, colon, lungs, breasts, prostate, or ovaries, leukemia, neuroblastomas, eczema, acne; improved wrinkle resistance, skin hydration, sebum secretions
08/14/2008US20080194533 Sulfating 17 beta-dihydroequilin or 17 beta-estradiol using tertiary amine-sulfur trioxide complexes and sodium, lithium or potassium salt formation; hormone replacement therapy; hot flashes in postmenopausal women; endometriosis, breast cancer
08/14/2008US20080194532 Ophthalmic or cosmetic oil-in-water emulsions containing a cetylalkylammonium halide, a vegetable oil, a surfactant and one of riluzole, fusidic acid, latanoprost, loratadine, tacrolimus, naphazoline or ketanserin; nontoxic
08/14/2008US20080194531 Methods for Treating Visual Disorders
08/14/2008US20080194530 Chemical Compounds
08/14/2008US20080194529 Deuterated 3-(1-Methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin- -5-yl)-N-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-4-propoxy-benzenesulfonamide; combined with a second active agent; erectile dysfunction; hypotensive agents
08/14/2008US20080194528 Stable, anhydrous mixture of a Vitamin D derivative, such as {5-[4'-(1-ethyl-1-hydroxypropyl)-6-methyl-2'-propylbiphenyl-3-yloxymethyl]-2-hydroxymethylphenyl}methanol; topical treatment of psoriasis
08/14/2008US20080194527 Compositions and combinations 2
08/14/2008US20080194526 Concentrate comprising a S1P receptor agonist selected from 2-amino-2-[2-(4-octylphenylethyl)]propane-1,3-diol, 2-amino-2-[4-(benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propane-diol, and 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}azetidine-3-carboxylic acid
08/14/2008US20080194525 Process of Making Geminal Bisphosphonic Acids and Pharmaceutically Acceptable Salts and/or Hydrates Thereof
08/14/2008US20080194524 Compounds For the Inhibition of Undesired Cell Proliferation and Use Thereof
08/14/2008US20080194523 Diethyl[2-({[7-[(4-fluorophenyl)methyl]-4-hydroxy-3-({[2-(methyloxy)ethyl]amino}carbonyl)-2-oxo-1,5-naphthyridin-1(2H)-yl]acetyl}amino)ethyl]phosphonate; alone or with a second enzyme inhibitor
08/14/2008US20080194522 Substituted benzopyran-2-ones; competitive binding ligands for MAO inhibition; anxiolytic agents; neurodegenerative diseases, nervous system disorders; drug screening by comparing detectable changes in fluorescence when samples are oxidatively deaminated in the presence of a MAO
08/14/2008US20080194521 Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
08/14/2008US20080194520 Sulfonyl Amino Cyclic Derivatives and Use Thereof
08/14/2008US20080194519 Topiramate and a cyclodextrin in an injectible dosage form to be administered when oral administration has been interrupted; neuroprotectants; suitable for treating neonatal seizures
08/14/2008US20080194518 Antimicrobial Compositions
08/14/2008US20080194517 Equine or canine immunomodulating composition and treatment method
08/14/2008US20080194516 System for managing anti-coagulant infusions in patients
08/14/2008US20080194515 Extracting DNA from a blood or buccal cell sample, PCR, resolution, and identification of differences in sequences between the extracted DNA and PCR primers; drug screening
08/14/2008US20080194514 Methods and Compositions for Inhibiting the Function of Polynucleotide Sequences
08/14/2008US20080194513 RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF OCULAR NEOVASCULARIZATION